Genocea Biosciences (GNCAQ) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock GNCAQ vs. VRPX, SCPS, STAB, EVLO, SMFL, CMRA, GNCA, ARDS, PXMD, and CALAShould you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Statera Biopharma (STAB), Evelo Biosciences (EVLO), Smart for Life (SMFL), Comera Life Sciences (CMRA), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), PaxMedica (PXMD), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry. Genocea Biosciences vs. Its Competitors Virpax Pharmaceuticals Scopus BioPharma Statera Biopharma Evelo Biosciences Smart for Life Comera Life Sciences Genocea Biosciences Aridis Pharmaceuticals PaxMedica Calithera Biosciences Genocea Biosciences (NASDAQ:GNCAQ) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership. Which has stronger earnings and valuation, GNCAQ or VRPX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenocea BiosciencesN/AN/AN/AN/AN/AVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/A Is GNCAQ or VRPX more profitable? Genocea Biosciences' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Genocea BiosciencesN/A N/A N/A Virpax Pharmaceuticals N/A -1,554.34%-338.29% Does the media favor GNCAQ or VRPX? In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score. Company Overall Sentiment Genocea Biosciences Neutral Virpax Pharmaceuticals Neutral Do institutionals & insiders have more ownership in GNCAQ or VRPX? 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, GNCAQ or VRPX? Genocea Biosciences has a beta of 1.74, meaning that its stock price is 74% more volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Do analysts prefer GNCAQ or VRPX? Given Genocea Biosciences' higher probable upside, research analysts plainly believe Genocea Biosciences is more favorable than Virpax Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genocea Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryGenocea Biosciences beats Virpax Pharmaceuticals on 4 of the 7 factors compared between the two stocks. Get Genocea Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GNCAQ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNCAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart GNCAQ vs. The Competition Export to ExcelMetricGenocea BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$6K$283.41M$5.78B$9.92BDividend YieldN/AN/A6.67%4.51%P/E RatioN/AN/A75.8626.67Price / SalesN/A473.70556.21121.26Price / CashN/A22.4437.1158.92Price / BookN/A11.0511.436.07Net IncomeN/A-$115.81M$3.29B$266.42M Genocea Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070VRPXVirpax Pharmaceuticals0.1019 of 5 stars$0.01flatN/A-99.9%$14KN/A0.007Gap DownSCPSScopus BioPharmaN/A$0.00-40.0%N/AN/A$13KN/A0.009STABStatera BiopharmaN/A$0.00+100.0%N/A-83.3%$11KN/A0.0020Gap UpEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120Options VolumeSMFLSmart for LifeN/A$0.00+1,000.0%N/A-96.6%$8K$11.11M0.00110Gap DownCMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/AN/AN/AN/A$5KN/A0.0030PXMDPaxMedicaN/A$0.00+100.0%N/AN/A$2KN/A0.002Gap UpCALACalithera BiosciencesN/A$0.00flatN/A-99.0%$1KN/A0.0060 Related Companies and Tools Related Companies Virpax Pharmaceuticals Competitors Scopus BioPharma Competitors Statera Biopharma Competitors Evelo Biosciences Competitors Smart for Life Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors PaxMedica Competitors Calithera Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNCAQ) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genocea Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNCAQ Stock Alerts